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Angiosarcoma (AS) is a rare and aggressive vascular neoplasm with very poor prognosis. Patients with extensive cutaneous AS who
are not surgical candidates have very limited options since there is no standard treatment. Treatment options include radiation,
chemotherapy, and angiogenesis inhibitor with varying success rates. Here, we report a case an 88 year old patient with extensive
scalp angiosarcoma having biopsy proven remission with bevacizumab and radiotherapy without undergoing surgery.
1.Introduction
Angiosarcoma (AS) is a rare and aggressive vascular neo-
plasm comprising less than 2% of all soft tissue sarcomas [1–
3]. Angiosarcomas comprise approximately 15% of all head
andnecksarcomas[4–6]andlessthan1%ofallmalignancies
in the region [6, 7]. Head and neck ASs are frequently seen
in the scalp [1–3, 6–15] and are common in the elderly
population with the mean age greater than 60 years. AS also
has a slight predilection for Caucasian patients and the male
gender [1, 2, 7–10, 12–14] .P r o g n o s i si sp o o rs i n c eA Si s
very aggressive with disease-free survival of less than 50%
at ﬁve years [1, 4, 5, 8–14] due to its high propensity for
local recurrence [4, 5, 8, 11]. However, some studies report
survival of 10–20% after ﬁve years [1, 5, 8–11], which may
indicate lesions that are located in the scalp and face have a
lower survival rate and higher rate of recurrence [10]. The
most important prognostic factors include tumor size and
ability to achieve negative margins with tumor grade also
being considered to be a prognostic factor for recurrence
[5, 12]a n do v e r a l ls u r v i v a l[ 11]. Patients with facial or
scalp AS of less than 5cm in size tend to do better than
those with tumor size greater than 5cm [6, 10]. Patients
with cutaneous AS who are not surgical candidates due
to multiple comorbid conditions have limited treatment
options. Due to its rapid progression, achieving local control
and prevention of metastasis in AS has been a challenge.
Few reports have described successful treatment of AS using
adjuvant chemotherapy with radiotherapy [16]. Diﬀerent
treatment modalities used in cutaneous angiosarcoma are
depicted in Table 1. Here, we report a successful response of
AS to bevacizumab with concurrent radiation therapy in a
patient not eligible for surgical intervention.
2.CaseReport
An 88-year-old Caucasian male with a 37-pack-year history
of smoking noticed purplish lumps on his scalp with scaling
and erythema for two months prior to presentation. He
had a complicated past medical history of Stage II prostate
cancer treated with radiation treatments, abdominal aortic
aneurysm repair, macular degeneration treated with pho-
todynamic therapy, torn retina, inguinal hernia repair, and
four-vessel coronary artery bypass graft. The patient noted
the violaceous papules increasing in size and nodularity and
extending down to the level of the eyebrows bilaterally. He2 Sarcoma
Table 1: Diﬀerent treatments used in cutaneous angiosarcoma.
Reference Type of
literature Angiosarcoma type Treatment Outcome
Koontz et al.
2008 [16] Case reports (1) Nasal area (1) Bevacizumab + XRT + SX (1) CR, 26 mos response duration
(2) Nasal area (2) Bevacizumab + XRT + SX (2) CR, 8.5 mos response duration
Gkalpakiotis
et al. 2008 [17] Case report Well-diﬀerentiated
exophytic-face
XRT alone
Phase 1: 45Gy
Phase 2: 20Gy
5yrs remission
Schlemmer
et al. 2008 [18]
Retrospective
study
32 patients Paclitaxel 5/8 PR (mean 5.8mos)
8 scalp and facial ± Sx 1/8 CR (42mos)
Rest other sites ± XRT 1/8 PD (3mos)
± chemotherapy 1/8 NC (2mos)
Nagano et al.
2007 [19]
Retrospective
study 9 patients Cutaneous AS
Docetaxel with or without
other previous treatment
(XRT, SX)
6/9: major response (2 CR, 4 PR)
2CR: 2 XRT without SX
4P R :1X R T+S X ,1X R Tw i t h o u t
SX, 1 SX without XRT, 1 without
SX nor XRT
Holloway et al.
2005 [20] Case report Cutaneous AS (scalp) Liposomal doxorubicin + XRT 4years response duration
Eiling et al.
2002 [21] Case report Cutaneous AS (scalp) Liposomal doxorubicin + XRT
CR with cervical lymph node
metastasis disappearance
4mos response duration
Lankester et al.
1999 [22] Case report Cutaneous AS (face
and scalp)
Liposomal daunorubicin +
XRT 15mos CR
CR: complete response, PR: partial response, NC: no change, PD: progression of disease, XRT: radiotherapy, SX: surgery.
initially thought the mass was a bruise, but the increase in
size prompted him to consult a physician. On examination,
the patient had multiple irregularly shaped lesions, largest of
which was a 4cm × 7cm on the frontal scalp; these lesions
were violaceous papules with scaling and erythema as shown
in Figure 1. A PET scan showed uptake only on the scalp
adjacent to the frontal bone near midline (Stage IIA—T2a
N0 M0).
3.Histology
Biopsy of the lesion showed irregular channels and ectatic
vascular spaces lined by plump hyperchromatic endothelial
cells. The histology results were most compatible with mod-
erately diﬀerentiated angiosarcoma, as shown in Figure 2,i n
low magniﬁcation (L) and high magniﬁcation (R).
4. Treatment andFollowup
Due to the extent of the disease and his frail state, the patient
was a poor surgical candidate; resection, if performed, would
have necessitated the removal of his entire scalp, from ear
to ear. The patient was started on one pre-irradiation cycle
of bevacizumab, which was continued through his course
of radiation therapy. Bevacizumab was given 5mg/kg IV
(with calculated dose of 350mg) every two weeks while on
radiation therapy, total of four treatments. His tumor total
radiation treatment dose was 6000rad, in 30 fractions, over
46 days. The patient tolerated the treatment well with skin
changes characterized only by erythema and desquamation
with residual crusting of the skin. Marked clinical improve-
ment was noted. Side eﬀects also included slight swelling
of the eyes with yellowish discharge and pruritus from the
radiation treatment. No hypertension or proteinuria was
noted. A repeat biopsy performed six months after treatment
showed ﬁbrosing granulation tissue, ﬁbrosis, hemosiderin
deposition, and dilated vessels not reminiscent of the pattern
seen in the original angiosarcoma as shown in Figure 3.
Seven months after the completion of bevacizumab and
radiation therapy, the patient had a biopsy-proven local
recurrence. He was started immediately on an increased dose
ofbevacizumab10mg/kgIVeverytwoweeks,whichhetoler-
ated well for three months for a total of 6 doses. He then had
a minor stroke, and bevacizumab was discontinued. Weekly
paclitaxel was initiated at 80mg/m2 and continued for 15
treatments with stable disease. Progression occurred and
treatment was changed to pegylated doxorubicin 40mg/m2
monthly × 2 treatments without beneﬁt. He expired 23
months after initial presentation due to disease.
5. Discussion
Angiosarcoma usually presents as a purple macular ulcerated
lesion that is often mistaken for a bruise. Cutaneous
angiosarcoma may be categorized as being idiopathic AS of
the face and scalp, primary AS of the breast, postradiationSarcoma 3
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Figure 2
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AS, or AS arising from chronic lymphedema of the extremity
[9, 10, 23]. Proposed risk factors for developing cutaneous
AS include exposure to vinyl chloride, insecticides, tho-
rium dioxide, and hormones such as anabolic steroids and
synthetic estrogen [5, 12]. It is also postulated that sun-
damaged skin may be a risk factor due to its predilection
for Caucasians; however, there is no direct evidence to
support this theory [1, 23]. A combination of surgery
and radiotherapy oﬀers the best survival and is the most
common treatment modality used for this very aggressive
tumor [9, 12]. Surgery remains the ﬁrst option for treating
patients with angiosarcoma of the scalp, but due to its
rapid progression, patients may present with disseminated
or extensive local disease which make surgery inappropriate4 Sarcoma
[1, 8–15]. Postoperative radiotherapy is employed routinely
as it improves survival [5, 7, 8], although there is still an
extremely high rate of recurrence and local failure [12]. The
role of chemotherapy, however, is not well established and
h a sn o tb e e np r o v e nt oi n c r e a s es u r v i v a l[ 12].
As a result of the above-mentioned challenges, treatment
options are limited, especially since AS is often found in
elderly patients who may have many comorbidities and
are more prone to adverse treatment reactions. Prospective
studies with regard to adjuvant chemotherapy and other
treatment combinations are also limited due to the rarity of
the disease so there are no speciﬁc guidelines with regards
to treatment. Radiation therapy dose response has been
suggested wherein those receiving greater than 5000 rad have
better local control, though larger case numbers are required
to validate initially reported successes [5]. There are case
reports of remission with radiotherapy alone; these cases
tendtobewell-diﬀerentiatedandexophyticformsofAS[17].
The addition of another therapy to radiation therapy has
seen some support over the years; diﬀerent cases showed AS
responding to radiation when biological, angiomodulation,
and/or tubulin-aﬃnic substances are given in conjunction
with radiation therapy [5, 16, 18–20, 23–26]. Nevertheless,
the overwhelming opinion about chemotherapy is that
its utility remains largely undeﬁned [5]. Major responses
have also been reported with paclitaxel, but side eﬀects
are dose limiting [24, 25]. A retrospective study done on
32 advanced angiosarcoma patients by the soft tissue and
bone sarcoma EORTC group has 62% response rate in
advancedangiosarcomaswithpaclitaxel,with6outof8scalp
and face angiosarcomas responding [18]. There are 6 scalp
angiosarcomapatientsintheEORTCstudy,with3previously
treated with radiation therapy (2 with partial response and
1 with progression of disease) and 1 previously treated with
doxorubicin (no change with paclitaxel). However, there has
been a complete response for 42 months on one patient
with scalp angiosarcoma without previous therapy and no
previous surgery. Another taxane drug, docetaxel, has been
used for cutaneous AS; a retrospective study of nine patients
in Japan reported a major response in six patients with
reduced neutropenia and peripheral neuropathy compared
to paclitaxel [19]. Published case reports have cited a partial
response without surgery [26] and a sustained complete
response after surgery in a patient four years later [20]
following the addition of liposomal doxorubicin [20, 21,
26]. Eiling et al. reported a case of conﬁrmed histological
tumor regression of a nonresectable radioresistant scalp
angiosarcoma and cervical lymph node metastasis treated
with pegylated liposomal doxorubicin [21]. Complete remis-
sion with liposomal daunorubicin with radiotherapy in
unresectable AS has also been published [22].
Although our patient had a moderately diﬀerentiated AS,
the tumor location, the extent of disease, the patient’s age,
and his comorbidities all pointed to a very poor prognosis.
Due to the extent of our patient’s disease, it would have
been diﬃcult to achieve a tumor-free margin surgically
without any disﬁguring eﬀects, and radiotherapy alone was
initially thought to be insuﬃcient. It is diﬃcult to assess
whether our patient’s response is due to radiotherapy alone
similar to the case reported by Gkalpakiotis et al. [17]
or if bevacizumab improved our patient’s response since
vascular endothelial growth factor was overexpressed in 80%
of angiosarcoma cases [27]. To our knowledge, this case is
the only one to report remission of AS after treatment with
bevacizumab and radiotherapy without surgical interven-
tion. In two case reports from the Duke University, 5mg/kg
of bevacizumab was used in one patient and 10mg/kg for
the other in conjunction with radiotherapy as postsurgical
treatment [16]. Our patient was given four treatments of
5mg/kg of bevacizumab with radiation therapy as a primary
treatment without surgical resection and achieved complete
clinical response with a negative pathology on biopsy
remission. Due to the lack of resection, we cannot report a
complete pathologic response. A second course involving a
higher dose of bevacizumab for his recurrence led to clinical
responseafterthreemonthsbuthadtobediscontinuedwhen
patient had a stroke, a known risk of bevacizumab though a
meta-analysis done based on 5 randomized controlled trials
among 2,288 patients receiving bevacizumab showed no
statistical diﬀerence of stroke incidence compared to control
[28].
With AS being very aggressive and having a very low ﬁve-
year survival rate, therapy with bevacizumab in conjunction
with radiation therapy or as a primary therapy may be one
option to improve survival outcomes especially in patients
who are not surgical candidates. Currently, there are two
phase II clinical trials studying the use of bevacizumab for
AS which were not available during our patient’s initial
diagnosis. One is an open-label multicenter phase II trial
assessing the median disease-free progression of AS with
the treatment of bevacizumab alone [29]. The other is the
studyofaddingbevacizumabtothecombinedchemotherapy
of gemcitabine and docetaxel in the treatment of diﬀerent
types of sarcoma including AS [30]. Both trials are currently
recruiting patients. A prospective clinical trial regarding
neoadjuvant therapy with bevacizumab possibly also includ-
ing chemotherapy would be an interesting approach. In the
absence of speciﬁc treatment guidelines for AS, the addition
of bevacizumab to radiation may be one option to oﬀer hope
to patients who are deemed nonsurgical candidates.
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